NOT TO BE RELEASED, RELEASED OR DISTRIBUTED, IN WHOLE OR IN PART, IN, IN OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE APPLICABLE LAWS OR REGULATIONS OF SUCH JURISDICTION.
THIS NOTICE FALLS UNDER RULE 2.8 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “TAKEOVER RULES”). THIS NOTICE CONTAINS INTERNAL INFORMATION.

Statement by Sanofi on Horizon Therapeutics plc (“Horizon”)

Paris, December 112022. Sanofi SA (“Sanofi”) regularly evaluates a variety of business development opportunities, including evaluating a potential transaction with Horizon. As transaction price expectations do not meet our value creation criteria, Sanofi announces that it is no longer in discussions with Horizon and does not intend to bid for Horizon.
This announcement shall be treated as a declaration to which Rule 2.8 of the Takeover Rules applies.

Around Sanofi
We are an innovative global healthcare company driven by one purpose: we hunt the wonders of science to improve people’s lives. Located in approximately 100 countries, our team is dedicated to transforming medical practice by working to make the impossible possible. We bring potentially life-changing treatments and life-saving immunizations to millions of people around the world, while putting sustainability and social responsibility at the heart of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Sandrine Gundoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Eve Berland | +1 215 432 0234 | evan.berland@sanofi.com
Nicholas Obrist | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.com
Victor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com

Investor Relations
Eva Schäfer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.com
Arnaud Delépine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.com
Corentine Driancourt | + 33 6 40 56 92 21 |